Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets ...

Valued at a market cap of $8 billion, Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.2% year on year to $316.2 million. Its non-GAAP profit of $0.56 per share was ...

The market expects Techne (TECH) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...

For the quarter ended March 2025, Techne (TECH) reported revenue of $316.18 million, up 4.2% over the same period last year. EPS came in at $0.56, compared to $0.48 in the year-ago quarter.

The latest price target for Bio-Techne (NASDAQ:TECH) was reported by UBS on May 9, 2025. The analyst firm set a price target for $70.00 expecting TECH to rise to within 12 months (a possible 42.86 ...

1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of ...

New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne ...

MINNEAPOLIS (AP) — MINNEAPOLIS (AP) — Techne Corp. (TECH) on Wednesday reported fiscal third-quarter net income of $22.6 million. The Minneapolis-based company said it had net income of 14 ...